The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | ctDNA as an early outcome predictor in patients with 2L LBCL treated with liso-cel versus SoC
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses the value of circulating tumor DNA (ctDNA) as an early outcome predictor in patients with second-line large B-cell lymphoma (2L LBCL) treated with lisocabtagene maraleucel (liso-cel) versus standard of care (SoC) in the Phase III TRANSFORM trial (NCT03575351). Dr Kamdar highlights that low baseline ctDNA levels correlated with higher event-free survival (EFS). Patients treated with liso-cel also demonstrated higher evidence of measurable residual disease (MRD) negativity, highlighting the clinical benefit of liso-cel compared with SoC. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
